Sinopharm Group (1099) Q3 2025 earnings summary

Executive summary

• CNMDC reported consolidated unaudited financial results for the nine months ended 30 September 2025, showing declines in key financial metrics compared to the same period last year.

Financial highlights

• Revenue for the period was RMB 54.69 billion, down 2.41% year-over-year.

• Operating profit reached RMB 962.11 million, a decrease of 10.34% compared to the same period last year.

• Total comprehensive income attributable to owners was RMB 395.28 million, down 2.71% year-over-year.

• Net cash flow from operating activities was negative RMB 4.13 billion, a 49.55% improvement from the prior year's negative RMB 8.18 billion.

Key financial ratios and metrics

• Total assets at period end were RMB 64.13 billion, up 4.01% from the beginning of the period.

• Total equity attributable to owners was RMB 8.19 billion, up 3.86% from the start of the period.